Background:A combined fexofenadine/pseudoephedrine(FEX/PSE)tablet is approved in Japan for treatment of allergic rhinitis. The FEX/PSE package insert was recently amended to avoid misunderstanding of treatment duration, particularly when prescribed for >2 weeks. Objective:To assess whether FEX/PSE treatment duration in clinical practice is appropriate. Methods:In this post hoc analysis of the post‒marketing DEPARTURE drug use‒results survey, we analyzed the time course of discontinuation, incidence of adverse drug reactions(ADRs), physician‒assessed efficacy, and patient‒reported outcomes (PRO) in 3 cohorts. Cohort A included patients who discontinued because of improvement or continued treatment for ≧8 weeks(n=607), Cohort B included patients who discontinued because of inefficacy or an ADR(n=103), and Cohort C included patients who discontinued for other reasons(n=202). Results:Median(interquartile range)treatment duration was 44(21‒63), 15(13‒28), and 23.5(15‒38)days in Cohorts A, B, and C, respectively. Cohort A exhibited 2 peaks of discontinuation(2‒3 weeks;9‒10 weeks), likely reflecting early efficacy and pollinosis duration, and had significant improvements in efficacy and PRO. ADRs were infrequent(2.0%)and not associated with prolonged treatment. In Cohort B, FEX/PSE was appropriately discontinued early after an ADR or inefficacy. The ADR incidence was high(40.8%), with minimal improvements in symptoms and PRO. In Cohort C, 94.6% of discontinuations could not be medically justified. Cohort C had moderate improvements and ADRs were infrequent(1.5%). Conclusion:FEX/PSE treatment duration is adjusted appropriately in most Japanese patients with allergic rhinitis, although one‒fifth of early discontinuation could not be medically justified.